Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Open accessThe DOI matches its Crossref record; 306 of the 306 references it cites were found in a registry or an index.
Abstract
Worldwide, nearly 40% of adults are overweight and 13% are obese. Health consequences of excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, and increased mortality. Treating obesity is challenging and calorie restriction often leads to rebound weight gain. Treatments such as bariatric surgery create hesitancy among patients due to their invasiveness. GLP-1 medications have revolutionized weight loss and can reduce body weight in obese patients by between 15% and 25% on average after about 1 year. Their mode of action is to mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism and satiety. However, GLP-1 drugs carry known risks and, since their use for weight loss is recent, may carry unforeseen risks as well. They carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) are fairly common while pancreatitis and intestinal obstruction are rarer. There may be a loss of lean body mass as well as premature facial aging. A significant disadvantage of using these medications is the high rate of weight regain when they are discontinued. Achieving success with pharmacologic treatment and then weaning to avoid future negative effects would be ideal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our results show pleiotropic anti-inflammatory and antioxidant effects that may mechanistically underlie the cardiovascular, hepatic, and renal protection consistently seen in large-scale cardiovascular outcome studies (45, 46), in addition to their well-established benefits on glycemic control and weight reduction (47, 48).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Even highly efficacious GLP-1 agonists face challenges, including variable response rates, gastrointestinal side effects, and weight regain after discontinuation.”
From The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities (2026) · cites this paper as [35]
In the citing paper
“Symptoms such as reduced appetite, early satiety, and nausea may limit dietary variety and protein intake, leading to muscle loss [63,64,65].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 4×
“Similarly, the subcutaneously once weekly formulation of the GLP-1 receptor agonist semaglutide showed equally promising results for weight maintenance [132].”
InfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 5×
“Recent studies have now demonstrated the strongest weight loss effect with the dual agonist for GLP-1 and GIP, upwards of 22% over 1 year [134].”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 2×
“For instance, the SELECT trial demonstrated the cardiovascular benefit of the GLP-1 receptor agonist semaglutide beyond that of weight loss [125].”
Chooi, Y. C., Ding, C., & Magkos, F. (2019) · Metabolism · doi:10.1016/j.metabol.2018.09.005 · Cited by 2,737 · cited 1×
“Therefore, although BMI is appreciated for its simplicity in categorizing subjects, it should be used with caution as a diagnostic tool and might be better used as a screening aid [10]. a non-communicable pandemic that continues to expand and a ff ect over 1 globally [11–14].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“The Satiety and Clinical Adiposity Liraglutide Evidence (SCALE) trial demonstrated one-third of patients lost 10% of their body weight in 1 year with sustained weight loss demonstrated at 2 years [149,150].”
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“While there are newer and even more potent anti-obesity drugs on the horizon, semaglutide still garners attention for its non-diabetic and non-obesity benefits, specifically cardiovascular risk reduction, as well as improving renal outcomes [125,153].”
Obesity Phenotypes, Diabetes, and Cardiovascular Diseases
Piché, M.-E., Tchernof, A., & Després, J.-P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316101 · Cited by 1,986 · cited 1×
“…proin fl ammatory cytokines and adi-pokines The inflammatory environment incites endothelial dysfunction further contributing to cardiovascular risk and hypertension [22–24]. in fl ammatory environment incites endothelial dysfunction further contributing cardiovascular risk and hypertension [22–24].”
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966 · cited 2×
“However, over the years, many studies have shown no differences in achieving weight loss from a variety of macronutrient approaches [45] and calorie reduction is likely the more successful approach for weight loss maintenance [250,251].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811 · cited 2×
“Therefore, should be used aid [10].”
Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726 · cited 1×
“Numerous studies have demonstrated that dietary macronutrient composition is not the most significant contributing factor for weight loss [44–46].”
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665 · cited 2×
“The lipid pro fi le in obesity is marked by an increase in triglycerides and free fa tt y acids [20].”
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“A number of clinical trials in persons with diabetes have been subsequently performed and frequently cited for the clinical efficacy of exendin-4 [147,148].”
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 1×
“Randomized double-blinded placebo-controlled withdrawal studies were performed in both semaglutide and tirzepatide with crossover to placebo at 20 weeks and 36 weeks, respectively [242,243].”
The role of depot fat in the hypothalamic control of food intake in the rat
Kennedy, G. C. (1953) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1953.0009 · Cited by 1,425 · cited 1×
“The concept that body fat storage may be regulated was first proposed by Kennedy et al. through the concept of a “set point” [2].”
Benefits and Risks of Bariatric Surgery in Adults: A Review
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020) · JAMA · doi:10.1001/jama.2020.12567 · Cited by 1,251 · cited 1×
“Possible complications of the gastric bypass include bowel obstruction and malabsorption, while possible complications of the sleeve gastrectomy include venous thromboembolism and gastroesophageal reflux disease [78,79].”
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 1×
“As expected, there was weight regain, but there still was an overall 5.6% net loss of weight by the end of 120 weeks [244].”
InfluentialWadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 1×
“Persistence of the weight loss plateau (or presumed weight loss maintenance) occurred up until 104 weeks [133].”
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036 · cited 1×
“For instance, the Contrave Obesity Research studies (COR-I, COR II, COR-BMOD, and COR diabetes) were performed over a 56-week period [64,65].”
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“In rodent models, the majority of POMC/CART neurons have GLP-1 receptors, predominantly in the arcuate nucleus of the hypothalamus [118].”
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 2×
“Developing treatment paradigms for weight loss maintenance remain focused on decreasing hunger, despite the compensatory decrease in energy expenditure [94].”
The Mediterranean diet and health: a comprehensive overview
Guasch‐Ferré, M., & Willett, W. C. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13333 · Cited by 940 · cited 1×
“These include favorable effects on heart and brain health and decreased diabetes risk [55,56].”
Maintenance of Lost Weight and Long-Term Management of Obesity
Hall, K. D., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.012 · Cited by 876 · cited 1×
“The drivers for weight regain are hypometabolism and hyperphagia in the weight-reduced state [229–231].”
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868 · cited 1×
“The follow-up STEP-5 trial demonstrated that semaglutide could sustain weight loss over 104 weeks or nearly 2 years [152].”
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 3×
“7.9 6.9 [224] Liraglutide 56 weeks 6.2 (after 6% loss on low-calorie diet alone) 1.9 [131] Tirzepatide (GLP-1/GIP dual agonist) 36 weeks 20.9% 14 [243] Abbreviations: GLP-1—glucagon-like peptide-1; GIP—glucose-dependent insulinotropic polypeptide.”
Influentialle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 1×
“…with overweight or obese and prediabetes taking liraglutide had a reduced risk for developing type 2 diabetes with greater weight loss compared to those taking a placebo [151] Arguably, the arrival of semaglutide more than five years later sparked the public’s attention to GLP-1 agonist therapy.”
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Brehm, B. J., Seeley, R. J., Daniels, S. R., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021480 · Cited by 830
O’Brien, P. E., Hindle, A., Brennan, L., Skinner, S., Burton, P., Smith, A., Crosthwaite, G., & Brown, W. (2019) · Obesity Surgery · doi:10.1007/s11695-018-3525-0 · Cited by 815 · cited 1×
“Upwards of 20 years has seen a sustained 22% weight loss [294].”
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“The Satiety and Clinical Adiposity Liraglutide Evidence (SCALE) trial demonstrated one-third of patients lost 10% of their body weight in 1 year with sustained weight loss demonstrated at 2 years [149,150].”
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716 · cited 1×
“Qsymia has demonstrated overall efficacy for weight loss maintenance, achieving sustained weight loss of 9-10% at the 108-week mark compared to 1.8% for placebo [67].”
InfluentialGardner, C. D., Trepanowski, J. F., Del Gobbo, L. C., Hauser, M. E., Rigdon, J., Ioannidis, J. P. A., Desai, M., & King, A. C. (2018) · JAMA · doi:10.1001/jama.2018.0245 · Cited by 709 · cited 1×
“Numerous studies have demonstrated that dietary macronutrient composition is not the most significant contributing factor for weight loss [44–46].”
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680 · cited 1×
“A synthetic version of exendin-4 was approved by the FDA in 2005 for glycemic control in type 2 diabetics [145,146].”
Persistent metabolic adaptation 6 years after “The Biggest Loser” competition
Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Knuth, N. D., Brychta, R., Chen, K. Y., Skarulis, M. C., Walter, M., Walter, P. J., et al. (2016) · Obesity · doi:10.1002/oby.21538 · Cited by 672 · cited 1×
“This can be attributed to the persistent effects of metabolic adaptation, the phenomena seen in weight regulation that may cause weight regain and potentially a weight loss plateau [223].”
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Humans against Obesity: Who Will Win?
Caballero, B. (2019) · Advances in Nutrition · doi:10.1093/advances/nmy055 · Cited by 638
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“The mechanisms behind this usually involved brown adipose tissue thermogenesis [98,99].”
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
The Effects of Exercise and Physical Activity on Weight Loss and Maintenance
Swift, D. L., McGee, J. E., Earnest, C. P., Carlisle, E., Nygard, M., & Johannsen, N. M. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.014 · Cited by 536 · cited 1×
“While this does seem to be true over the lower ranges of physical activity, with the upper ranges of physical activity the energy expenditure appears to plateau, consistent with a “constrained total energy expenditure model” [255,256].”
Jakicic, J. M., Marcus, B. H., Gallagher, K. I., Napolitano, M., & Lang, W. (2003) · JAMA · doi:10.1001/jama.290.10.1323 · Cited by 519
Calorie restriction with or without time-restricted eating in weight loss
Liu, D., Huang, Y., Huang, C., Yang, S., Wei, X., Zhang, P., Guo, D., Lin, J., Xu, B., Li, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114833 · Cited by 516 · cited 1×
“However, over the years, many studies have shown no differences in achieving weight loss from a variety of macronutrient approaches [45] and calorie reduction is likely the more successful approach for weight loss maintenance [250,251].”
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · cited 1×
“GLP-1 action in the hindbrain reduced food intake and body weight over time [240].”
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · cited 1×
“This drug leads to a weight loss nadir at around 36 weeks with a weight regain that happens at around 52 weeks [62].”
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462 · cited 2×
“At 3 years of follow-up, tirzepatide use led to a sustained mean loss of weight of 20% with less likelihood of deterioration to diabetes in persons with obesity and prediabetes when compared to placebo [137].”
InfluentialObesity as a Disease: The Obesity Society 2018 Position Statement
Jastreboff, A. M., Kotz, C. M., Kahan, S., Kelly, A. S., & Heymsfield, S. B. (2019) · Obesity · doi:10.1002/oby.22378 · Cited by 457 · cited 1×
“Obesity as defined by The Obesity Society (TOS) is a multi-factorial chronic disease that results from excess fat accumulation that presents a risk to health [1].”
Obesity and the risk of cardiometabolic diseases
Valenzuela, P. L., Carrera-Bastos, P., Castillo-García, A., Lieberman, D. E., Santos-Lozano, A., & Lucia, A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00847-5 · Cited by 452 · cited 2×
“The cardiometabolic consequences of The cardiometabolic consequences of obesity such as insulin resistance, glucose intolerance, type 2 diabetes, arterial hypertension, atherosclerosis, and dyslipidemia are all stressors on the heart and vascular system [18,19].”
Biology's response to dieting: the impetus for weight regain
MacLean, P. S., Bergouignan, A., Cornier, M.-A., & Jackman, M. R. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00755.2010 · Cited by 446 · cited 3×
“7.9 6.9 [224] Liraglutide 56 weeks 6.2 (after 6% loss on low-calorie diet alone) 1.9 [131] Tirzepatide (GLP-1/GIP dual agonist) 36 weeks 20.9% 14 [243] Abbreviations: GLP-1—glucagon-like peptide-1; GIP—glucose-dependent insulinotropic polypeptide.”
InfluentialIncreased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435 · cited 1×
“Furthermore, patients with type 2 diabetes are inherently at higher risk of pancreatitis [165].”
Association of body mass index with health care expenditures in the united states by age and sex
Ward, Z. J., Bleich, S. N., Long, M. W., & Gortmaker, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247307 · Cited by 428 · cited 1×
“Therefore, although BMI is appreciated for its simplicity in categorizing subjects, it should be used with caution as a diagnostic tool and might be better used as a screening aid [10]. a non-communicable pandemic that continues to expand and a ff ect over 1 globally [11–14].”
Discovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418 · cited 1×
“The additional properties of inhibition of glucagon secretion and inhibition of caloric intake accelerated the development of GLP-1 receptor agonists for usage in type 2 diabetes management [86].”
Bariatric Surgery: Risks and Rewards
Pories, W. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1641 · Cited by 405
Attenuated GLP-1 secretion in obesity: cause or consequence
Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394
Short-Term Medical Benefits and Adverse Effects of Weight Loss
Pi-Sunyer, F. X. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-7_part_2-199310011-00019 · Cited by 392 · cited 1×
“Rapid weight loss has long been associated with biliary disease, sarcopenia, and alopecia [170–174].”
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391 · cited 2×
“…[174] “Ozempic face” Cosmetic procedures such as facelift, dermatologic fillers, autologous fat transfer [177,178] Sarcopenia Exercise (emphasize resistance-training), increase protein intake [171,180] Gastroparesis with anesthesia Discontinue at least one week prior to procedure [158,217]”
Tobias, D. K., Chen, M., Manson, J. E., Ludwig, D. S., Willett, W., & Hu, F. B. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00367-8 · Cited by 373 · cited 1×
“The low-or very-low fat intake approach is recommended for inducing significant short-term weight loss, but its long-term efficacy is not superior to dietary interventions with higher fat content [48].”
Effect of Exercise on 24-Month Weight Loss Maintenance in Overweight Women
Jakicic, J. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1550 · Cited by 370 · cited 1×
“For instance, those with high levels of physical activity are more successful at weight loss maintenance [257–259].”
Obesity energetics: body weight regulation and the effects of diet composition
Hall, K. D., & Guo, J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.052 · Cited by 367 · cited 1×
“Energy balance is dependent on nutrient intake and subsequent nutrient oxidation rates [89,90].”
Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00271-7 · Cited by 359 · cited 2×
“A growing number of trials have studied the beneficial impact of GLP-1 agonists on metabolic dysfunction associated with steatotic liver disease (MASLD), chronic kidney disease, as well as cardiovascular disease [121–124].”
Weight-loss maintenance for 10 years in the National Weight Control Registry
Thomas, J. G., Bond, D. S., Phelan, S., Hill, J. O., & Wing, R. R. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2013.08.019 · Cited by 358 · cited 1×
“A large public database known as the National Weight Control Registry (NWCR) was the first study to identify participants who were successful at weight loss and follow them over a 10-year period, with an attempt to identify variables that were associated with success [245].”
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · cited 4×
“…low fiber foods, reduce consumption of dairy, coffee, alcohol [156] Constipation Encourage physical activity, hydration, ample fiber in diet [156] Pancreatitis Discontinue drug, standard treatment for pancreatitis [156] Alopecia Change to a different GLP-1 medication, topical hair loss…”
InfluentialLong-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02996-7 · Cited by 347 · cited 2×
“While there is optimism that continuing use of GLP-1 treatments will preserve weight loss, most other anti-obesity strategies, including surgical interventions, generally have weight recidivism [127].”
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.2525 · Cited by 334 · cited 1×
“However, earlier studies showed inconsistences of GIP as a cause of weight loss, although more recent studies have demonstrated increased weight loss efficacy [280–283].”
Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2023) · doi:10.1101/2023.11.21.23298775 · Cited by 334
Constrained Total Energy Expenditure and Metabolic Adaptation to Physical Activity in Adult Humans
Pontzer, H., Durazo-Arvizu, R., Dugas, L. R., Plange-Rhule, J., Bovet, P., Forrester, T. E., Lambert, E. V., Cooper, R. S., Schoeller, D. A., & Luke, A. (2016) · Current Biology · doi:10.1016/j.cub.2015.12.046 · Cited by 326 · cited 1×
“While this does seem to be true over the lower ranges of physical activity, with the upper ranges of physical activity the energy expenditure appears to plateau, consistent with a “constrained total energy expenditure model” [255,256].”
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322 · cited 1×
“However, earlier studies showed inconsistences of GIP as a cause of weight loss, although more recent studies have demonstrated increased weight loss efficacy [280–283].”
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321 · cited 1×
“GLP-1 secretion seems to be impaired in obese subjects, which informs at least the partial role of GLP-1 in the pathophysiology of obesity [94–96].”
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320 · cited 2×
“All studies are in agreement that the greatest risk if any does occur in the initial months or year of therapy [200–204].”
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318 · cited 1×
“It is unclear whether those without type 2 diabetes using GLP-1 for weight loss are at the same risk [197,198].”
The energy balance model of obesity: beyond calories in, calories out
Hall, K. D., Farooqi, I. S., Friedman, J. M., Klein, S., Loos, R. J., Mangelsdorf, D. J., O’Rahilly, S., Ravussin, E., Redman, L. M., Ryan, D. H., et al. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac031 · Cited by 315 · cited 1×
“The drivers for weight regain are hypometabolism and hyperphagia in the weight-reduced state [229–231].”
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · cited 1×
“However, this has not translated over to human studies [100–102].”
Wang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300 · cited 1×
“…and health outcomes in over 1.9 million persons over an average of 3.68 years based on data from the US Department of Veterans Affairs and found, in addition to gastrointestinal and other common symptoms, a significant increase in hypotension, joint pain, kidney stones, and nephrolithiasis [190].”
InfluentialWorsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review
Bain, S. C., Klufas, M. A., Ho, A., & Matthews, D. R. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13538 · Cited by 299 · cited 1×
“A somewhat paradoxical effect has been demonstrated with GLP-1 usage and other agents for type 2 diabetes in which rapid improvement in glycemia results in worsening of retinopathy [193].”
Green, M., Arora, K., & Prakash, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082890 · Cited by 293 · cited 1×
“Finally, the microbiome has a variety of mechanisms through which it affects obesity, and pre/probiotic therapies could be a helpful addition to a weight loss regimen [58,59].”
Speakman, J. R., Levitsky, D. A., Allison, D. B., Bray, M. S., de Castro, J. M., Clegg, D. J., Clapham, J. C., Dulloo, A. G., Gruer, L., Haw, S., et al. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.008698 · Cited by 290 · cited 1×
“This model of body fat regulation was widely adopted in the 1990s with the discovery of leptin [3,4].”
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · cited 1×
“GLP-1 is a hormone released from the enteroendocrine cells of the small bowel in response to the arrival of a nutrient bolus [83].”
A systematic review of variables associated with the relationship between obesity and depression.
Preiss, K., Brennan, L., & Clarke, D. (2013) · Obesity Reviews · doi:10.1111/obr.12052 · Cited by 285 · cited 1×
“Psychological well-being is an important aspect of both eating behaviors and weight loss [264,265].”
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280 · cited 1×
“GLP-1 receptor agonist drug development began in earnest in 2005 with the approval of exenatide, a synthetic form of a natural peptide hormone isolated from the saliva of the venomous lizard Gila monster [144].”
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275 · cited 1×
“Parks and Rosebrough first expressed concerns regarding human safety with liraglutide as early rodent trials demonstrated an increased risk of medullary thyroid carcinoma [199].”
The melanocortin pathway and control of appetite-progress and therapeutic implications
Baldini, G., & Phelan, K. D. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0596 · Cited by 272 · cited 1×
“The opposing pathway is the agouti-related peptide (AgRP) neurons which stimulate hunger and increase food intake, often referred to as the orexigenic pathway [117].”
Obstructive sleep apnea and obesity: implications for public health
McFarlane, S. I. (2017) · Sleep Medicine and Disorders: International Journal · doi:10.15406/smdij.2017.01.00019 · Cited by 266 · cited 1×
“In this condition, excessive adiposity may restrict the lungs and impede their inflation, and adipose tissue in the diaphragm may compromise muscle strength, leading to intermittent hypoxia and hypercapnia [36,37].”
Central and peripheral GLP-1 systems independently suppress eating
Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265 · cited 1×
“The peripheral GLP-1 system and the central preproglucagon neurons within the brain stem have not been linked and appear to function independently of each other [106,115].”
Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
Dossat, A. M., Lilly, N., Kay, K., & Williams, D. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3262-11.2011 · Cited by 256
Early and late complications of bariatric operation.
Lim, R., Beekley, A., Johnson, D. C., & Davis, K. A. (2018) · Trauma Surgery & Acute Care Open · doi:10.1136/tsaco-2018-000219 · Cited by 248 · cited 1×
“Possible complications of the gastric bypass include bowel obstruction and malabsorption, while possible complications of the sleeve gastrectomy include venous thromboembolism and gastroesophageal reflux disease [78,79].”
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242 · cited 2×
“The most often reported side effects are nausea and vomiting which are a result of activation of specific GLP-1 receptors in the hindbrain and these symptoms can be mitigated with gradual dose escalation [155–157]. is disrupted or maintained during weight loss with GLP-1 agonists is ,184].”
Zhou, X.-D., Chen, Q.-F., Yang, W., Zuluaga, M., Targher, G., Byrne, C. D., Valenti, L., Luo, F., Katsouras, C. S., Thaher, O., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102848 · Cited by 238 · cited 1×
“Severe obesity, which is defined as a BMI over 40 kg/m 2 , is an alarming public health issue [6].”
Lockie, S. H., Heppner, K. M., Chaudhary, N., Chabenne, J. R., Morgan, D. A., Veyrat-Durebex, C., Ananthakrishnan, G., Rohner-Jeanrenaud, F., Drucker, D. J., DiMarchi, R., et al. (2012) · Diabetes · doi:10.2337/db11-1556 · Cited by 237 · cited 1×
“The mechanisms behind this usually involved brown adipose tissue thermogenesis [98,99].”
Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G. S., Chowansky, A., Zimmer, D., De Jonghe, B. C., Kanoski, S. E., Grill, H. J., & Bence, K. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.001 · Cited by 234 · cited 1×
“Reductions in food intake and body weight have been found, implying that both the hypothalamus and brainstem are important in the control of energy intake and body weight [119,120].”
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
GLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220 · cited 1×
“There are conflicting data in animal models regarding GLP-1-related drugs stimulating energy expenditure [97].”
Polidori, D., Sanghvi, A., Seeley, R. J., & Hall, K. D. (2016) · Obesity · doi:10.1002/oby.21653 · Cited by 209 · cited 1×
“However, if one were to choose a mechanism to prevent weight regain, targeting hunger would seem to be the better alternative due to the greater effect of metabolic adaptation on hunger, rather than the decrease in energy expenditure [235].”
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1710 · Cited by 208 · cited 1×
“The effect of tirzepatide on energy expenditure appears negligible, therefore making the effect on energy intake the most impactful [284].”
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207 · cited 1×
“Despite the overall efficacy of the incretin-based treatments for weight loss, there is a lack of long-term controlled studies beyond about 4 years available [221,222].”
Wettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.5.g984 · Cited by 197
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193 · cited 1×
“The initial attention in the clinical space for GLP-1 was related to the glucose-dependent insulin secretion effect, often referred to as the incretin effect [85].”
Varra, F.-N., Varras, M., Varra, V.-K., & Theodosis‑Nobelos, P. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13219 · Cited by 190 · cited 2×
“Obesity leads to oxidative stress from proinflammatory cytokines and adipokines [21]. leads to oxidative stress from proin fl ammatory cytokines and adi-pokines The inflammatory environment incites endothelial dysfunction further contributing to cardiovascular risk and hypertension [22–24]. in fl…”
Chawla, S., Tessarolo Silva, F., Amaral Medeiros, S., Mekary, R., & Radenkovic, D. (2020) · Nutrients · doi:10.3390/nu12123774 · Cited by 185 · cited 1×
“Exceeding 6-12 months of use may have undesired effects by increasing LDL cholesterol and cardiovascular risk in some studies, but others have found no difference [50–53].”
Kindel, T. L., Wang, A. Y., Wadhwa, A. N., Schulman, A. R., Sharaiha, R. Z., Kroh, M., Ghanem, O. M., Levy, S. M., Joshi, G. P., & LaMasters, T. L. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.08.033 · Cited by 184 · cited 1×
“A recent multi-society joint guidance statement advocated for an individualized approach based upon each patient’s unique factors rather than a one-size approach of holding this medication for all patients undergoing procedures [215].”
Common causes of hair loss – clinical manifestations, trichoscopy and therapy
Alessandrini, A., Bruni, F., Piraccini, B. M., & Starace, M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17079 · Cited by 173
Gardner, C. D., Vadiveloo, M. K., Petersen, K. S., Anderson, C. A. M., Springfield, S., Van Horn, L., Khera, A., Lamendola, C., Mayo, S. M., Joseph, J. J., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001146 · Cited by 172 · cited 1×
“However, guidelines have started to include a more nuanced understanding that there is a synergy between dietary nutrients and their food sources [47].”
Role of Physical Activity for Weight Loss and Weight Maintenance
Cox, C. E. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0013 · Cited by 167 · cited 1×
“For instance, those with high levels of physical activity are more successful at weight loss maintenance [257–259].”
Maintaining large weight losses: The role of behavioral and psychological factors.
Wing, R. R., Papandonatos, G., Fava, J. L., Gorin, A. A., Phelan, S., McCaffery, J., & Tate, D. F. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0014159 · Cited by 166 · cited 1×
“Successful weight loss management is often associated with low levels of depression [266,267].”
Bays, H. E., Kirkpatrick, C. F., Maki, K. C., Toth, P. P., Morgan, R. T., Tondt, J., Christensen, S. M., Dixon, D. L., & Jacobson, T. A. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.04.001 · Cited by 166 · cited 2×
“The cardiometabolic consequences of The cardiometabolic consequences of obesity such as insulin resistance, glucose intolerance, type 2 diabetes, arterial hypertension, atherosclerosis, and dyslipidemia are all stressors on the heart and vascular system [18,19].”
Dissociable hindbrain GLP1R circuits for satiety and aversion
Huang, K.-P., Acosta, A. A., Ghidewon, M. Y., McKnight, A. D., Almeida, M. S., Nyema, N. T., Hanchak, N. D., Patel, N., Gbenou, Y. S. K., Adriaenssens, A. E., et al. (2024) · Nature · doi:10.1038/s41586-024-07685-6 · Cited by 166 · cited 1×
“The most often reported side effects are nausea and vomiting which are a result of activation of specific GLP-1 receptors in the hindbrain and these symptoms can be mitigated with gradual dose escalation [155–157]. is disrupted or maintained during weight loss with GLP-1 agonists is ,184].”
Weight loss strategies and the risk of skeletal muscle mass loss
McCarthy, D., & Berg, A. (2021) · Nutrients · doi:10.3390/nu13072473 · Cited by 163 · cited 1×
“Newer strategies for weight maintenance have focused on preserving or even increasing lean body mass to counteract the decreases in energy expenditure thereby allowing for sustained weight loss [105,263].”
Jensen, A. B., Renström, F., Aczél, S., Folie, P., Biraima-Steinemann, M., Beuschlein, F., & Bilz, S. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06484-8 · Cited by 161 · cited 1×
“GLP-1 agonists are being explored as an adjunctive therapy to combine with bariatric surgery to avoid the weight regain that can occur post-surgery [81,82].”
Successful weight loss maintenance: A systematic review of weight control registries
Paixão, C., Dias, C. M., Jorge, R., Carraça, E. V., Yannakoulia, M., de Zwaan, M., Soini, S., Hill, J. O., Teixeira, P. J., & Santos, I. (2020) · Obesity Reviews · doi:10.1111/obr.13003 · Cited by 158 · cited 1×
“Other studies confirm the importance of dietary restraint and physical activity in preventing weight regain [247,248].”
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154 · cited 2×
“GLP-1 receptors have been identified in numerous areas of the central nervous system (CNS) including the area postrema, hypothalamus, lateral parabrachial nucleus, nucleus accumbens, nucleus tract solitarius, and the vagal efferent neurons [106–109].”
Córdova, R., Kliemann, N., Huybrechts, I., Rauber, F., Vamos, E. P., Levy, R. B., Wagner, K., Viallon, V., Casagrande, C., Nicolas, G., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.08.009 · Cited by 154 · cited 1×
“Processed foods are difficult to remove from the population’s food supply and public diets, due to their ubiquity as well as their low cost, convenience, and appealing taste [252,253].”
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 153 · cited 1×
“It is interesting to note that proglucagon and proglucagon-derived peptides (e.g., GLP-1, glucagon-like peptide-2, oxyntomodulin) are present in a small group of neurons in the nucleus tract solitarius within the brainstem and are another source of endogenous GLP-1 production [113,114].”
Bethel, M. A., Diaz, R., Castellana, N., Bhattacharya, I., Gerstein, H. C., & Lakshmanan, M. C. (2021) · Diabetes Care · doi:10.2337/dc20-1815 · Cited by 151 · cited 1×
“It is important to monitor patients on therapy [194–196].”
Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2024) · mBio · doi:10.1128/mbio.02032-23 · Cited by 150 · cited 1×
“While the brain does produce GLP-1, most circulating GLP-1 is gut-derived [110,111].”
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025) · Obesity Reviews · doi:10.1111/obr.13841 · Cited by 149 · cited 1×
“…[174] “Ozempic face” Cosmetic procedures such as facelift, dermatologic fillers, autologous fat transfer [177,178] Sarcopenia Exercise (emphasize resistance-training), increase protein intake [171,180] Gastroparesis with anesthesia Discontinue at least one week prior to procedure [158,217]”
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147 · cited 1×
“Newer anti-obesity medications are being developed that have promise for altering energy expenditure, although these are multi-receptor agonists involving binding both GLP-1 receptors and receptors such as glucagon which has been associated with increased energy expenditure [104].”
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145 · cited 1×
“The most often reported side effects are nausea and vomiting which are a result of activation of specific GLP-1 receptors in the hindbrain and these symptoms can be mitigated with gradual dose escalation [155–157]. is disrupted or maintained during weight loss with GLP-1 agonists is ,184].”
Knuth, N. D., Johannsen, D. L., Tamboli, R. A., Marks-Shulman, P. A., Huizenga, R., Chen, K. Y., Abumrad, N. N., Ravussin, E., & Hall, K. D. (2014) · Obesity · doi:10.1002/oby.20900 · Cited by 144 · cited 1×
“However, even during active weight loss, metabolic adaptation seems to be set into motion, and in fact may be triggered by achieving 11% of total body weight loss [236,237].”
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142 · cited 1×
“Drugs are in development to combat muscle loss during fat loss [290].”
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142 · cited 2×
“However, challenges remain in such multi-agonist receptor treatments, and the focus remains predominantly on energy intake [105].”
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Song, Y., Koehler, J. A., Baggio, L. L., Powers, A. C., Sandoval, D. A., & Drucker, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.009 · Cited by 140 · cited 1×
“However, in a murine model, knockout of glucagon genes originating from the bowel elicited no increase in food intake, and thus appetite suppression is attributed to GLP-1 produced within the CNS [112].”
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
del Olmo-Garcia, M. I., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 138 · cited 1×
“Beyond 12 monthsStable dose Well-controlled HbA1c, prevention of long-term diabetes complications, weight loss maintained [123,124,132,158] Abbreviations: GLP-1—glucagon-like peptide-1; HbA1c—hemoglobin A1c.”
Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance
Reiner, D. J., Mietlicki-Baase, E. G., McGrath, L. E., Zimmer, D. J., Bence, K. K., Sousa, G. L., Konanur, V. R., Krawczyk, J., Burk, D. H., Kanoski, S. E., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3579-15.2016 · Cited by 133 · cited 1×
“Reductions in food intake and body weight have been found, implying that both the hypothalamus and brainstem are important in the control of energy intake and body weight [119,120].”
Similarities and Differences between Weight Loss Maintainers and Regainers: A Qualitative Analysis
Reyes, N. R., Oliver, T. L., Klotz, A. A., Lagrotte, C. A., Veur, S. S. V., Virus, A., Bailer, B. A., & Foster, G. D. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2011.11.014 · Cited by 130
A comprehensive diagnostic approach to detect underlying causes of obesity in adults
van der Valk, E. S., van den Akker, E. L. T., Savas, M., Kleinendorst, L., Visser, J. A., Van Haelst, M. M., Sharma, A. M., & van Rossum, E. F. C. (2019) · Obesity Reviews · doi:10.1111/obr.12836 · Cited by 129
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126 · cited 1×
“Monoclonal antibodies such as bimagrumab, trevogrumab, and garetosmab, prevent muscle loss by blocking the activation of receptors within the myostatin-activin-follistatin-inhibin system that cause muscle mass to decrease [291].”
Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes
Ahrén, B. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199808)20:8<642::aid-bies7>3.0.co;2-k · Cited by 125 · cited 1×
“The potential application of GLP-1 in diabetes was recognized as early as 1998 [143].”
Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P. (2024) · BMJ · doi:10.1136/bmj-2023-078225 · Cited by 125 · cited 1×
“In contrast, a more recent Scandinavian trial did not detect a significant association between GLP-1 usage and thyroid cancer [202].”
Cao, C., Yang, S., & Zhou, Z. (2020) · Endocrine · doi:10.1007/s12020-020-02223-6 · Cited by 124 · cited 1×
“The large and long-duration GLP-1 cardiovascular outcome trials did not show an increase in pancreatitis [166].”
Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.002 · Cited by 124 · cited 1×
“The popularity of GLP-1 receptor analogs may have to do with their profound effects on the CNS. Early studies demonstrated the anorectic actions of GLP-1 on the hypothalamus [238,239].”
Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines
Fu, X., Wang, Y., Zhao, F., Cui, R., Xie, W., Liu, Q., & Yang, W. (2023) · Aging · doi:10.18632/aging.204847 · Cited by 124 · cited 1×
“Other health issues associated with obesity include depression, anxiety, and chronic kidney disease [38–40].”
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122 · cited 3×
“…In addition to nausea and vomiting, other GI-related side effects include diarrhea, constipation, dyspepsia, decreased appetite, and abdominal pain [158–160]. particularly be needed for ffl icted with sarcopenic obesity, a condition of a mismatch between It is estimated that around 80–90% of…”
Mauldin, K., May, M. S., & Clifford, D. E. (2022) · Nutrition in Clinical Practice · doi:10.1002/ncp.10885 · Cited by 118 · cited 1×
“Other studies confirm the importance of dietary restraint and physical activity in preventing weight regain [247,248].”
Obesity and Endothelial Function
Kajikawa, M., & Higashi, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10071745 · Cited by 115 · cited 1×
“…proin fl ammatory cytokines and adi-pokines The inflammatory environment incites endothelial dysfunction further contributing to cardiovascular risk and hypertension [22–24]. in fl ammatory environment incites endothelial dysfunction further contributing cardiovascular risk and hypertension [22–24].”
The impact of obesity: a narrative review
Lam, B. C. C., Lim, A. Y. L., Chan, S. L., Yum, M. P. S., Koh, N. S. Y., & Finkelstein, E. A. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-232 · Cited by 115
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Is regular exercise an effective strategy for weight loss maintenance?
Foright, R. M., Presby, D. M., Sherk, V. D., Kahn, D., Checkley, L. A., Giles, E. D., Bergouignan, A., Higgins, J. A., Jackman, M. R., Hill, J. O., et al. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.01.025 · Cited by 113 · cited 1×
“While most of the interventions are based on targeting hunger and energy expenditure, there is little understanding of whether physical activity or exercise plays a role [254].”
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Drummond, R. F., Seif, K. E., & Reece, E. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.08.024 · Cited by 113
Katsurada, K., Maejima, Y., Nakata, M., Kodaira, M., Suyama, S., Iwasaki, Y., Kario, K., & Yada, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.116 · Cited by 112 · cited 1×
“GLP-1 receptors have been identified in numerous areas of the central nervous system (CNS) including the area postrema, hypothalamus, lateral parabrachial nucleus, nucleus accumbens, nucleus tract solitarius, and the vagal efferent neurons [106–109].”
Mechanisms controlling hormone secretion in human gut and its relevance to metabolism
Martin, A. M., Sun, E. W., & Keating, D. J. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0399 · Cited by 109 · cited 1×
“However, in the last 20 years, the gastrointestinal system has been identified as the largest endocrine organ and has demonstrated the key role of gut hormones in energy homeostasis [5].”
D’Alessandro, A., & De Pergola, G. (2018) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2017.1417978 · Cited by 105 · cited 1×
“These include favorable effects on heart and brain health and decreased diabetes risk [55,56].”
Watson, C. J., Whitledge, J. D., Siani, A. M., & Burns, M. M. (2020) · Journal of Medical Toxicology · doi:10.1007/s13181-020-00814-3 · Cited by 104 · cited 1×
“The usage of compounding pharmacies does come with risks as the medications produced are not FDA-regulated [141].”
Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L. (2023) · Nature Medicine · doi:10.1038/s41591-023-02344-1 · Cited by 104
GLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Lando, H. M., Alattar, M., & Dua, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11290.or · Cited by 102 · cited 1×
“Early studies on patients with type 2 diabetes treated with incretin therapy including GLP-1s and dipeptidyl ) inhibitors did demonstrate an association between drug usage and lipase and amylase suggesting a mechanism of pancreatic inflammation [161,162].”
Subclassification of obesity for precision prediction of cardiometabolic diseases
Coral, D., Smit, F., Farzaneh, A., Gieswinkel, A., Tajes, J. F., Sparsø, T., Delfin, C., Bauvin, P., Wang, K., Temprosa, M. G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03299-7 · Cited by 98 · cited 1×
“…body notably on the cardiovascular and endocrine Obesity has harmful effects on various body systems, most notably on the cardiovascular and endocrine systems, but also on the kidneys, liver, lungs, joints, and immune system [17]. systems, but also on the kidneys , joints, and immune system [17].”
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2343092 · Cited by 97 · cited 2×
“GLP-1 medications can cause a range of side effects related to the gastrointestinal system as well as changes in muscle mass and effects on the appearance of the face and loss of hair (Figure 2). been further corroborated by other investigators [181].”
Richard, J. E., Farkas, I., Anesten, F., Anderberg, R. H., Dickson, S. L., Gribble, F. M., Reimann, F., Jansson, J.-O., Liposits, Z., & Skibicka, K. P. (2014) · Endocrinology · doi:10.1210/en.2014-1248 · Cited by 96
Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4346 · Cited by 96 · cited 1×
“Studies suggest that GLP-1 drugs are not a direct cause of depressive symptoms in weight loss [268].”
Why BMI is flawed — and how to redefine obesity
Prillaman, M. (2023) · Nature · doi:10.1038/d41586-023-03143-x · Cited by 92 · cited 2×
“The cardiometabolic consequences of The cardiometabolic consequences of obesity such as insulin resistance, glucose intolerance, type 2 diabetes, arterial hypertension, atherosclerosis, and dyslipidemia are all stressors on the heart and vascular system [18,19].”
Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk
Naude, C. E., Brand, A., Schoonees, A., Nguyen, K. A., Chaplin, M., & Volmink, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013334.pub2 · Cited by 91
The role of social support in weight loss maintenance: results from the MedWeight study
Karfopoulou, E., Anastasiou, C. A., Avgeraki, E., Kosmidis, M. H., & Yannakoulia, M. (2016) · Journal of Behavioral Medicine · doi:10.1007/s10865-016-9717-y · Cited by 90 · cited 1×
“Family encouragement and support have also been associated with successful weight loss management [271–273].”
Yeo, Y. H., Rezaie, A., Hsieh, T. Y.-J., Hu, X., Gaddam, S., Ma, K. S.-K., Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group, Mohamed, G., Lee, G. Y., Huang, P.-C., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0019 · Cited by 90 · cited 1×
“In an analysis of one US health systems database a 700% increase in GLP-1 prescribing over the past four years was noted, primarily driven by prescriptions for obesity [138].”
de Lima, E. P., Moretti, R. C., Pomini, K. T., Laurindo, L. F., Sloan, K. P., Sloan, L. A., de Castro, M. V. M., Baldi, E., Ferraz, B. F. R., Pereira, E. D. S. B. M., et al. (2024) · Biology · doi:10.3390/biology13070519 · Cited by 86
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 84 · cited 2×
“A common fi nding amongst all GLP-1 trials was that of increased heart rate attributed to a direct e ff ect on the pacemaker cells within the sinus node of the heart [185]. the development of pancreatitis [159].”
Tricò, D., Moriconi, D., Berta, R. D., Baldi, S., Quiñones-Galvan, A., Guiducci, L., Taddei, S., Mari, A., & Nannipieri, M. (2021) · Nutrients · doi:10.3390/nu13041345 · Cited by 83 · cited 1×
“For instance, high protein diet, Mediterranean-style diet, low carbohydrate diet, low-calorie diet, and low-fat diet are just several options [42,43].”
Esophageal cancer global burden profiles, trends, and contributors
Teng, Y., Xia, C., Cao, M., Yang, F., Yan, X., He, S., Cao, M., Zhang, S., Li, Q., Tan, N., et al. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0145 · Cited by 83
Tinsley, G. M., & Heymsfield, S. B. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae164 · Cited by 81 · cited 1×
“Patients should be aware of these potential unwanted effects and, to minimize loss of muscle mass, encouraged to participate in resistance exercises and increase protein intake [179].”
Gut microbiota in health and disease: advances and future prospects
Zhang, Y., Wang, H., Sang, Y., Liu, M., Wáng, Q., Yang, H., & Li, X. (2024) · MedComm · doi:10.1002/mco2.70012 · Cited by 80 · cited 1×
“Finally, the microbiome has a variety of mechanisms through which it affects obesity, and pre/probiotic therapies could be a helpful addition to a weight loss regimen [58,59].”
The genetics of lipid storage and human lipodystrophies
Robbins, A. L., & Savage, D. B. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.004 · Cited by 79 · cited 1×
“The energy-dense nature of fat makes it an efficient means of storing excess energy intake and thus the body favors fat for keeping energy in reserve [91,92].”
Longitudinal Analysis of Obesity Drug Use and Public Awareness
Berning, P., Adhikari, R., Schroer, A. E., Jelwan, Y. A., Razavi, A. C., Blaha, M. J., & Dzaye, O. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57232 · Cited by 78 · cited 1×
“While largely successful as an anti-diabetic drug therapy, the effects on both reducing food intake and promoting weight loss in persons with diabetes and animal models prompted further study as an anti-obesity medication [87,88].”
(2016) · PubMed Central · Cited by 77
Yap, M. K. K., & Misuan, N. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13169 · Cited by 77 · cited 1×
“A number of clinical trials in persons with diabetes have been subsequently performed and frequently cited for the clinical efficacy of exendin-4 [147,148].”
Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons
Humphrey, C. D., & Lawrence, A. C. (2023) · Facial Plastic Surgery · doi:10.1055/a-2148-6321 · Cited by 77 · cited 2×
“The rapid weight loss can be visualized in many areas of the body and one of these manifestations known as “Ozempic face” occurs when fat pads in the face are rapidly depleted [177,178].”
Lecoultre, V., Ravussin, E., & Redman, L. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1286 · Cited by 74 · cited 1×
“However, even during active weight loss, metabolic adaptation seems to be set into motion, and in fact may be triggered by achieving 11% of total body weight loss [236,237].”
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74 · cited 1×
“Emerging data have established that GLP-1 agonist administration has not increased the risk of malignancy outside of the thyroid gland and may in fact reduce the risk of malignancy with potential for preventive applications [203,204].”
Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels
Çalık Başaran, N., Dotan, I., & Dicker, D. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01461-2 · Cited by 71 · cited 1×
“The metabolic efficacy of bariatric surgery in increasing gut production of GLP-1 to supraphysiologic levels postprandially is considered a major factor in early weight loss [80].”
Evaluation of efficacy and safety of orlistat in obese patients
Jain, S., Ramanand, S., Ramanand, J., Akat, P., Patwardhan, M., & Joshi, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.81938 · Cited by 69 · cited 1×
“Patients are advised to consume a low-fat diet to combat the side effects of oily stool [61].”
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Chronic Kidney Disease: Its Relationship With Obesity
Prasad, R., Jha, R. K., & Keerti, A. (2022) · Cureus · doi:10.7759/cureus.30535 · Cited by 68 · cited 1×
“Other health issues associated with obesity include depression, anxiety, and chronic kidney disease [38–40].”
JAKICIC, J. M., APOVIAN, C. M., BARR-ANDERSON, D. J., COURCOULAS, A. P., DONNELLY, J. E., EKKEKAKIS, P., HOPKINS, M., LAMBERT, E. V., NAPOLITANO, M. A., & VOLPE, S. L. (2024) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003520 · Cited by 68
Catenacci, V. A., Odgen, L., Phelan, S., Thomas, J. G., Hill, J., Wing, R. R., & Wyatt, H. (2014) · Journal of Physical Activity and Health · doi:10.1123/jpah.2012-0250 · Cited by 67
Garvey, W. T. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2021.11.082 · Cited by 66 · cited 1×
“The conceptual framework for weight regain and weight loss maintenance is based on the theory that the human body acts to defend a particular body mass, via the hypothetical “settling point” of weight [226–228].”
Yoshida, Y., Joshi, P., Barri, S., Wang, J., Corder, A. L., O'Connell, S. S., & Fonseca, V. A. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108255 · Cited by 65
Mahamat‐Saleh, Y., Aune, D., Freisling, H., Hardikar, S. S., Jaafar, R. F., Rinaldi, S., Gunter, M. J., & Dossus, L. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02857-7 · Cited by 65
Cambi, M. P. C., Baretta, G. A. P., Magro, D. D. O., Boguszewski, C. L., Ribeiro, I. B., Jirapinyo, P., & de Moura, D. T. H. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05164-1 · Cited by 64 · cited 1×
“A supportive weight management team approach considers mood changes and how they can affect quality of life [269,270].”
Turnbull, C. D., Wang, S. H., Manuel, A. R., Keenan, B. T., McIntyre, A., Schwab, R. J., & Stradling, J. R. (2017) · Sleep And Breathing · doi:10.1007/s11325-017-1599-x · Cited by 63 · cited 1×
“In this condition, excessive adiposity may restrict the lungs and impede their inflation, and adipose tissue in the diaphragm may compromise muscle strength, leading to intermittent hypoxia and hypercapnia [36,37].”
Kim, Y.-H., Kim, S. M., Han, K.-D., Jung, J.-H., Lee, S.-S., Oh, S. W., Park, H. S., Rhee, E.-J., Lee, W.-Y., & Yoo, S. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010072 · Cited by 62 · cited 2×
“Kim et al. found a linear association between waist circumference and all-cause mortality in a study on 23,263,878 subjects over the age of 20 years [8]. although BMI is appreciated for its simplicity in categorizing Another reason fixation on BMI is not entirely accurate is because it does not…”
Obesity, Bariatric Surgery and Obstructive Sleep Apnea—A Narrative Literature Review
Wyszomirski, K., Walędziak, M. S., & Różańska-Walędziak, A. M. (2023) · Medicina · doi:10.3390/medicina59071266 · Cited by 62 · cited 1×
“Bariatric surgery is indicated in patients with a BMI above 40 independent of coexisting comorbidities or in patients with a BMI over 35 with a history of comorbidities such as type 2 diabetes or hypertension [71].”
Jackson, S. E., Steptoe, A., Beeken, R. J., Kivimäki, M., & Wardle, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104552 · Cited by 61 · cited 1×
“Successful weight loss management is often associated with low levels of depression [266,267].”
Recent advances in understanding body weight homeostasis in humans
Müller, M. J., Geisler, C., Heymsfield, S. B., & Bosy-Westphal, A. (2018) · F1000Research · doi:10.12688/f1000research.14151.1 · Cited by 61 · cited 1×
“The conceptual framework for weight regain and weight loss maintenance is based on the theory that the human body acts to defend a particular body mass, via the hypothetical “settling point” of weight [226–228].”
Differential mechanisms affecting weight loss and weight loss maintenance
Rosenbaum, M., & Foster, G. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00864-1 · Cited by 61
Wai, K. M., Mishra, K., Koo, E., Ludwig, C. A., Parikh, R., Mruthyunjaya, P., & Rahimy, E. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.04.010 · Cited by 61 · cited 1×
“It is important to monitor patients on therapy [194–196].”
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59 · cited 1×
“An even greater weight loss is seen with this novel dual agonist, achieving upwards of a 22.5% weight loss at 72 weeks [134–136].”
InfluentialSide Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
Seo, Y.-G. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20059 · Cited by 57 · cited 1×
“Early studies on patients with type 2 diabetes treated with incretin therapy including GLP-1s and dipeptidyl ) inhibitors did demonstrate an association between drug usage and lipase and amylase suggesting a mechanism of pancreatic inflammation [161,162].”
Objectively Measured Physical Activity and Sedentary Behavior in Successful Weight Loss Maintainers
Ostendorf, D. M., Lyden, K., Pan, Z., Wyatt, H. R., Hill, J. O., Melanson, E. L., & Catenacci, V. A. (2018) · Obesity · doi:10.1002/oby.22052 · Cited by 56 · cited 1×
“Data from the NWCR also suggest successful weight maintainers can spend upwards of one hour per day in light physical activity [262].”
Dell’Olio, A., Scott, W. T., Taroncher-Ferrer, S., Onofre, N. S., Soriano, J. M., & Rubert, J. (2024) · Microbiome · doi:10.1186/s40168-024-01975-x · Cited by 55 · cited 2×
“Obesity is billion people with multiple comorbidities habits, lifestyle, disruptions, and gut dysbiosis [15,16].”
Phentermine/Topiramate extended-release capsules (qsymia) for weight loss.
Lonneman, D. J., Rey, J. A., & McKee, B. (2013) · Europe PMC (PubMed Central) · Cited by 54
Janssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54 · cited 1×
“However, this has not translated over to human studies [100–102].”
Inaba, C. S., Koh, C. Y., Sujatha-Bhaskar, S., Silva, J. P., Chen, Y., Nguyen, D. V., & Nguyen, N. T. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.02.013 · Cited by 53 · cited 1×
“However, the overall weight loss is still significant, and surgical weight loss is ultimately a personal choice for patients as it does carry risks [295–297].”
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., Rhee, T. G., Cao, B., Teopiz, K. M., Wong, S., Le, G. H., Ho, R., & Kwan, A. T. H. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.062 · Cited by 53
Obesity: an evolutionary context
Speakman, J. R., & Elmquist, J. K. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac002 · Cited by 52 · cited 1×
“Energy balance is buffered by fat stores and the adipose compartment therefore potentially producing an obesogenic state [93].”
Alenzi, K. A. O., Alsuhaibani, D. S., Batarfi, B. S., & Alshammari, T. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364110 · Cited by 52
Discovery of GLP-1–Based Drugs for the Treatment of Obesity
Drucker, D. J. (2024) · New England Journal of Medicine · doi:10.1056/nejmcibr2409089 · Cited by 51 · cited 1×
“While largely successful as an anti-diabetic drug therapy, the effects on both reducing food intake and promoting weight loss in persons with diabetes and animal models prompted further study as an anti-obesity medication [87,88].”
Once-Weekly Semaglutide for Weight Management: A Clinical Review
Fornes, A., Huff, J., Pritchard, R. I., & Godfrey, M. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221092681 · Cited by 50 · cited 1×
“The general trajectory of weight loss with initiation of GLP-1 therapy has been well-studied (Table 2) [218–220].”
Is there evidence for a set point that regulates human body weight?
Müller, M. J., Bosy-Westphal, A., & Heymsfield, S. B. (2010) · F1000 Medicine Reports · doi:10.3410/m2-59 · Cited by 49 · cited 1×
“This model of body fat regulation was widely adopted in the 1990s with the discovery of leptin [3,4].”
Zhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4162 · Cited by 49 · cited 1×
“Headaches, dizziness, hypoglycemia, and injection site reactions have also been reported albeit to a much lesser degree [188,189].”
Mansour, M. R., Hannawa, O., Yaldo, M., Nageeb, E. M., & Chaiyasate, K. (2024) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2024.07.051 · Cited by 49 · cited 2×
“The rapid weight loss can be visualized in many areas of the body and one of these manifestations known as “Ozempic face” occurs when fat pads in the face are rapidly depleted [177,178].”
Kerem, L., & Stokar, J. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.3812 · Cited by 47 · cited 1×
“Data are still accumulating and no definitive answer has emerged [211,212].”
The Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 46 · cited 1×
“Therefore, most of the effect of weight loss via GLP-1-related pathways may be related to a decrease in energy intake, rather than the direct effects on energy expenditure [103].”
Cited by
Uti, D. E., Omang, W. A., Alum, E. U., Ugwu, O. P.-C., Wokoma, M. A., Oplekwu, I. R., Atangwho, I. J., & Egbung, G. E. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s529250 · Cited by 31
Sabatella, L., Ortega, P., Valentí, V., Rotellar, F., Pagola, A. U., Ahmed, A., Purkayastha, S., Tuero, C., Blanco, N., & Landecho, M. F. (2025) · Obesity · doi:10.1002/oby.70100 · Cited by 32
“This phenomenon has been clearly demonstrated in recent extension studies and real-world cohorts, underscoring the need for either continuous therapy or adjunctive strategies to sustain outcomes [46–48].”
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 28
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Metadata
- Authors
- Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J.
- Affiliations
- NYU Grossman Long Island School of Medicine (US)
- Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA
- Corresponding author
- Reiss, Allison B.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2025-03-13
- Volume
- 15
- Issue
- 3
- Pages
- 408
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC11940170
- OpenAlex
- W4408387882
- Semantic Scholar
- afb045c76cb862647622228026132eedba8d8b95
- Cited by
- 58
- References
- 304
- Citations by year
- 2026: 41 · 2025: 17
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- GLP-1 receptor agonists, obesity, weight loss, weight regain, drug discontinuation, satiety, multiple endocrine neoplasia type 2, gastrointestinal adverse effects, pancreatitis, intestinal obstruction, lean mass loss, facial aging
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.